Ethacrynic Acid
FDA-approved product (tablet, oral), marketed as Edecrin, Ethacrynate Sodium, Ethacrynic Acid.
- Registered studies
- 0
- Lab records
- 1
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Cirrhosis of liver
- Congestive heart failure
- Nephrotic syndrome
- Pulmonary edema
- Urinary system disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Aryloxyacetic acid derivatives
- FDA pharmacologic class
- Loop Diuretic FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- MRSA: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ethacrynic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Cabozantinib S-MalateExisting use: Cancer, Clear cell renal carcinoma, Hepatocellular carcinoma and 7 more64.4% AI-predicted activityagainst M. tuberculosis45 registered studies
- Fondaparinux SodiumExisting use: Deep vein thrombosis, Intermediate coronary syndrome, Myocardial infarction and 3 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MidazolamExisting use: Amnesia, Epilepsy, Seizure and 1 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Moricizine HydrochlorideExisting use: Cardiac arrhythmia64.4% AI-predicted activityagainst M. tuberculosis3 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm64.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection64.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PirtobrutinibExisting use: Mantle cell lymphoma, Neoplasm64.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EncorafenibExisting use: Cancer, Colorectal adenocarcinoma, Colorectal cancer and 5 more64.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EfavirenzExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 2 more63.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more63.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Acetophenazine MaleateExisting use: Psychosis63.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.